Breast Cancer Trial, Not Yet Recruiting
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- People who are able to understand and sign a dated consent form approved by an ethics board before any trial-related procedures begin.
- Women aged 18 or older who have advanced breast cancer.
- People whose breast cancer has been confirmed by laboratory testing and is either unable to be removed by surgery or has spread to other parts of the body, with evidence of the cancer returning or spreading.
- People whose breast cancer has been confirmed by a central laboratory to have high levels of a protein called HER2, following established medical guidelines.
- People who have at least one tumour that can be measured using a standard set of imaging guidelines known as RECIST 1.1.
- Women at any stage of menopause — including those who have not yet reached menopause, those who are in the transition period, and those who have already gone through menopause — are able to be enrolled.
- People who have previously received treatment for breast cancer that has returned or spread are able to be enrolled.
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- People with early stage breast cancer (rather than advanced or metastatic breast cancer).
- People whose breast cancer does not meet the laboratory testing criteria for high HER2 levels as described in the inclusion criteria (confirm with trial site).
- Women who are currently pregnant or breastfeeding.
- People considered unsuitable for the trial by the doctor overseeing the study.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: (022)65150123-8212
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Primary endpoints
To assess progression-free survival (PFS) of Chinese patients with advanced breast cancer with HER2 overexpression and HER2 underexpression treated with real-world T-DXd (DS8201).
Can't join this trial?
Data last synced from ClinicalTrials.gov: 30 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.